Ibrutinib
CR100955
Phase 3 small_molecule active
Quick answer
Ibrutinib for Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active